4.7 Article

Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016-2017 and 2017-2018 Epidemics in Canada

Journal

JOURNAL OF INFECTIOUS DISEASES
Volume 225, Issue 8, Pages 1387-1398

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiaa138

Keywords

influenza virus; influenza vaccine; vaccine effectiveness; genomics; subtype

Funding

  1. British Columbia Centre for Disease Control
  2. Ministere de la Sante et des Services Sociaux du Quebec
  3. l'Institut National de Sante Publique du Quebec
  4. Public Health Agency of Canada [1617-HQ-000083]
  5. Public Health Ontario
  6. Alberta Health

Ask authors/readers for more resources

This study investigates the genetic diversity of influenza A(H3N2) viruses and the impact of vaccination history on vaccine effectiveness. The findings show heterogeneity in vaccine effectiveness and suggest that pivotal mutations and repeat vaccination using unchanged antigen may reduce vaccine effectiveness.
During 2016-2017 and 2017-2018 influenza A(H3N2) epidemics, updated clade 3C.2a vaccine bore egg-adaptation mutations and circulating 3C.2a viruses showed substantial genetic diversity. Vaccine effectiveness by phylogenetic subcluster and prior vaccination history reveal informative heterogeneity underpinning subtype-specific findings. Background The influenza A(H3N2) vaccine was updated from clade 3C.3a in 2015-2016 to 3C.2a for 2016-2017 and 2017-2018. Circulating 3C.2a viruses showed considerable hemagglutinin glycoprotein diversification and the egg-adapted vaccine also bore mutations. Methods Vaccine effectiveness (VE) in 2016-2017 and 2017-2018 was assessed by test-negative design, explored by A(H3N2) phylogenetic subcluster and prior season's vaccination history. Results In 2016-2017, A(H3N2) VE was 36% (95% confidence interval [CI], 18%-50%), comparable with (43%; 95% CI, 24%-58%) or without (33%; 95% CI, -21% to 62%) prior season's vaccination. In 2017-2018, VE was 14% (95% CI, -8% to 31%), lower with (9%; 95% CI, -18% to 30%) versus without (45%; 95% CI, -7% to 71%) prior season's vaccination. In 2016-2017, VE against predominant clade 3C.2a1 viruses was 33% (95% CI, 11%-50%): 18% (95% CI, -40% to 52%) for 3C.2a1a defined by a pivotal T135K loss of glycosylation; 60% (95% CI, 19%-81%) for 3C.2a1b (without T135K); and 31% (95% CI, 2%-51%) for other 3C.2a1 variants (with/without T135K). VE against 3C.2a2 viruses was 45% (95% CI, 2%-70%) in 2016-2017 but 15% (95% CI, -7% to 33%) in 2017-2018 when 3C.2a2 predominated. VE against 3C.2a1b in 2017-2018 was 37% (95% CI, -57% to 75%), lower at 12% (95% CI, -129% to 67%) for a new 3C.2a1b subcluster (n = 28) also bearing T135K. Conclusions Exploring VE by phylogenetic subcluster and prior vaccination history reveals informative heterogeneity. Pivotal mutations affecting glycosylation sites, and repeat vaccination using unchanged antigen, may reduce VE.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available